Abstract
Chimeric antigen receptor (CAR) T cell immunotherapies have shown unprecedented success in treating leukemia but limited clinical efficacy in solid tumors. Here, we generated 1928zT2 and m28zT2, targeting CD19 and mesothelin, respectively, by introducing the Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 2 (TLR2) to 1928z and m28z. T cells expressing 1928zT2 or m28zT2 showed improved expansion, persistency and effector function against CD19+ leukemia or mesothelin+ solid tumors respectively in vitro and in vivo. In three patients with relapsed B cell acute lymphoblastic leukemia, a dose of 5×104/kg 1928zT2 T cells resulted in robust expansion and leukemia eradication and led to complete remission. Hence, our results demonstrate that TLR2 signaling can contribute to the efficacy of CAR T cells. We will present updates on the clinical trial. DisclosuresLi:Guangdong Zhaotai InVivo Biomedicine Co. Ltd.: Consultancy, Equity Ownership; Hunan Zhaotai Yongren Medical Innovation Co. Ltd.: Consultancy, Equity Ownership. Li:Guangdong Provincial Applied Science and Technology Research & Development Program (No. 2016B020237006): Research Funding; Guangdong Provincial Basic Research Program (No. 2015B020227003: Research Funding; National Natural Science Foundation of China (91642111): Research Funding; Guangzhou Science and Technology Project (No. 2015100010211): Research Funding.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
